Back In The Saddle: Texas Biotech Opexa Re-Enters The Clinic With MS Immunotherapy
This article was originally published in The Pink Sheet Daily
After a series of restructurings, a manufacturing upgrade, multiple meetings with FDA and a modest fundraising, Opexa is initiating a Phase IIb trial of its renamed T-cell immune therapy Tcelna, this time in secondary progressive MS.
You may also be interested in...
Biotech cuts staff by 30%, hoping for good news from Phase IIb trial due in the fourth quarter. Status of second candidate nearing the clinic is uncertain.